Vertex to Acquire Crinetics in $10 Billion Bet on Rare Endocrine Therapies
TL;DR Summary
Vertex will spend $10 billion to acquire Crinetics Pharmaceuticals, its largest-ever deal, expanding Vertex's portfolio in rare endocrine disorder therapies and signaling a major strategic move in biotech mergers and acquisitions.
- Compass says depression drug has long-lasting benefits STAT
- Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch Psychedelic Alpha
- Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment Moomoo
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile Business Wire
Reading Insights
Total Reads
1
Unique Readers
9
Time Saved
2 min
vs 2 min read
Condensed
92%
399 → 31 words
Want the full story? Read the original article
Read on STAT